Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 4, 2026, 9:54 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 313–336 of 22,011 matching trials from the live ClinicalTrials.gov search.

Filters: Recruiting Clear all

Conditions: Relapsed Non-Hodgkin Lymphoma, Refractory Non-Hodgkin Lymphoma, Non-Hodgkin Lymphoma, Large B-cell Lymphoma
Interventions: Rondecabtagene autoleucel (ronde-cel), Fludarabine, Cyclophosphamide; Drug
Lead sponsor: Lyell Immunopharma, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 270 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2031
U.S. locations: 32
States / cities: Irvine, California • Los Angeles, California • San Diego, California + 27 more

Conditions: Dysplastic Barrett's Esophagus, Radiofrequency Ablation, Barrett Esophagus
Interventions: Radiofrequency ablation alone; Diagnostic Test
Lead sponsor: Mayo Clinic; Other
Eligibility: 18 Years and older
Enrollment: 10 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2027
U.S. locations: 1
States / cities: Rochester, Minnesota

Conditions: NAFLD, PCOS
Interventions: Bicalutamide 50 mg, Placebo; Drug
Lead sponsor: University of California, San Francisco; Other
Eligibility: 18 Years to 42 Years · Female only
Enrollment: 50 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2028
U.S. locations: 1
States / cities: San Francisco, California

Conditions: Hepatocellular Carcinoma
Interventions: Hydroxychloroquine, Lipiodol, Placebo; Drug
Lead sponsor: VA Office of Research and Development; Federal
Eligibility: 18 Years and older
Enrollment: 93 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2030
U.S. locations: 1
States / cities: Philadelphia, Pennsylvania

Conditions: Patient Outcomes
Interventions: C3PO; Other
Lead sponsor: University of Oklahoma; Other
Eligibility: 18 Years and older
Enrollment: 187 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2031
U.S. locations: 1
States / cities: Oklahoma City, Oklahoma

Conditions: Glomerulonephritis, IGA, Immunoglobulin A Nephropathy
Interventions: Iptacopan; Drug
Lead sponsor: Novartis Pharmaceuticals; Industry
Eligibility: 18 Years to 99 Years
Enrollment: 20 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2027
U.S. locations: 9
States / cities: Birmingham, Alabama • Los Angeles, California • Orlando, Florida + 6 more

Conditions: Narcolepsy Type 1
Interventions: ALKS 2680 Dose 1, ALKS 2680 Dose 2, Placebo; Drug
Lead sponsor: Alkermes, Inc.; Industry
Eligibility: 18 Years to 70 Years
Enrollment: 150 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2027
U.S. locations: 15
States / cities: Brandon, Florida • Miami, Florida • Winter Park, Florida + 12 more

Conditions: Pancreatic Disease, Pancreatic Cancer, Pancreatic Cyst, Gastrointestinal Tumor, Bile Duct Diseases, Bile Duct Cancer, Lymph Node Disease, Submucosal Tumor of Gastrointestinal Tract, Gastrointestinal Cancer
Interventions: Endoscopic ultrasound examination; Device
Lead sponsor: Orlando Health, Inc.; Other
Eligibility: 18 Years to 100 Years
Enrollment: 140 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2028
U.S. locations: 1
States / cities: Orlando, Florida

Conditions: Depression
Interventions: Not listed
Lead sponsor: Duke University; Other
Eligibility: 13 Years and older
Enrollment: 35 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2022 – 2026
U.S. locations: 1
States / cities: Nashville, Tennessee

Conditions: Acute Ischemic Stroke From Large Vessel Occlusion
Interventions: ANA Funnel Catheter, Control; Device
Lead sponsor: Anaconda Biomed S.L.; Industry
Eligibility: 22 Years to 85 Years
Enrollment: 327 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2027
U.S. locations: 11
States / cities: Jacksonville, Florida • Atlanta, Georgia • Park Ridge, Illinois + 8 more

Conditions: Anesthesia, Surgery With General Anesthesia, Noncardiac Surgery, Hypotension During Surgery, Acute Kidney Injury (AKI), Myocardial Injury After Noncardiac Surgery (MINS), Vasopressor
Interventions: Norepinephrine, Phenylephrine; Drug
Lead sponsor: University of California, San Francisco; Other
Eligibility: 18 Years and older
Enrollment: 18,000 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2028
U.S. locations: 9
States / cities: San Francisco, California • College Park, Maryland • Ann Arbor, Michigan + 6 more

Conditions: Obsessive-Compulsive Disorder
Interventions: Ketamine, Naltrexone Pill, Placebo pill; Drug · Other
Lead sponsor: Stanford University; Other
Eligibility: 18 Years to 65 Years
Enrollment: 150 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2024 – 2028
U.S. locations: 1
States / cities: Stanford, California

Conditions: Fallopian Tube Carcinoma, Ovarian Carcinoma, Primary Peritoneal Carcinoma
Interventions: pUMVC3-hIGFBP-2 Multi-epitope Plasmid DNA Vaccine, Carboplatin, Computed Tomography, Magnetic Resonance Imaging, Biospecimen Collection; Biological · Drug · Procedure
Lead sponsor: University of Washington; Other
Eligibility: 18 Years and older · Female only
Enrollment: 26 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2028
U.S. locations: 1
States / cities: Seattle, Washington

Conditions: Parkinsons Disease (PD)
Interventions: Not listed
Lead sponsor: Washington University School of Medicine; Other
Eligibility: 40 Years and older
Enrollment: 120 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2025 – 2031
U.S. locations: 1
States / cities: St Louis, Missouri

Conditions: Hypertension
Interventions: Eat Well 6-months, Eat Well 12-months; Behavioral
Lead sponsor: Institute for Medical Research, Inc.; Other
Eligibility: 18 Years and older
Enrollment: 1,500 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2028
U.S. locations: 1
States / cities: Durham, North Carolina

Conditions: Healthy
Interventions: Magstim Rapid2; Device
Lead sponsor: University of Texas Southwestern Medical Center; Other
Eligibility: 18 Years to 39 Years
Enrollment: 50 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2020 – 2027
U.S. locations: 1
States / cities: Dallas, Texas

Conditions: Lung Cancer
Interventions: Portal Message with Reminder Text Messages, Text Message with Reminder Text Messages, Portal message only, Usual Care; Other
Lead sponsor: Wake Forest University Health Sciences; Other
Eligibility: 50 Years to 77 Years
Enrollment: 27,000 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2027
U.S. locations: 1
States / cities: Winston-Salem, North Carolina

Conditions: Nonalcoholic Steatohepatitis, Liver Fibrosis
Interventions: Synthroid, Placebo; Drug
Lead sponsor: VA Office of Research and Development; Federal
Eligibility: 18 Years to 75 Years
Enrollment: 128 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2029
U.S. locations: 1
States / cities: Columbia, Missouri

Conditions: HIV, Aging
Interventions: Customized activity plan, Customized nutrition plan; Other
Lead sponsor: Wake Forest University Health Sciences; Other
Eligibility: 50 Years and older
Enrollment: 100 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2026
U.S. locations: 1
States / cities: Winston-Salem, North Carolina

Conditions: Cervical Cancer, Hpv, Human Papilloma Virus, HPV Infection
Interventions: Evalyn® Brush, Copan Floqswab, CHW4CervicalHealth; Device · Behavioral
Lead sponsor: Thomas Jefferson University; Other
Eligibility: 25 Years to 65 Years · Female only
Enrollment: 120 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2025 – 2026
U.S. locations: 1
States / cities: Philadelphia, Pennsylvania

Conditions: Thyroid Gland Medullary Carcinoma
Interventions: Decision Aid, Questionnaire Administration; Other
Lead sponsor: M.D. Anderson Cancer Center; Other
Eligibility: 18 Years and older
Enrollment: 120 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2019 – 2028
U.S. locations: 1
States / cities: Houston, Texas

Conditions: Venous Thromboembolism (VTE)
Interventions: REGN7508, Apixaban; Drug
Lead sponsor: Regeneron Pharmaceuticals; Industry
Eligibility: 18 Years and older
Enrollment: 1,600 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2031
U.S. locations: 3
States / cities: Hialeah, Florida • New York, New York • El Paso, Texas

Conditions: Type 1 Diabetes (T1D), Sleep Health
Interventions: Sleep Health and Circadian Timing Intervention; Behavioral
Lead sponsor: University of Colorado, Denver; Other
Eligibility: 14 Years to 19 Years
Enrollment: 50 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2029
U.S. locations: 1
States / cities: Aurora, Colorado

Conditions: Breast Cancer, Metastatic Breast Cancer, Hormone Receptor-positive Breast Cancer, HER2-negative Breast Cancer
Interventions: Fulvestrant, Anastrozole, Abemaciclib; Drug
Lead sponsor: University of California, Irvine; Other
Eligibility: 18 Years and older
Enrollment: 20 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2031
U.S. locations: 1
States / cities: Orange, California

Search by objective public record fields.

Study of Rondecabtagene Autoleucel in Aggressive Large B-Cell Lymphoma

Impact of RFA on Esophageal Distensibility and Mucosal Impedance

Bicalutamide Therapy in Young Women With NAFLD and PCOS

Targeting Ischemia-Induced Autophagy Dependence in Hepatocellular Carcinoma

Program in Oncology for Tribal Health Systems.

Study to Evaluate the Impact of Iptacopan on Top of SOC on Biopsy Changes in Kidneys of Adult Patients With IgAN

A Study to Evaluate the Efficacy, Safety and Tolerability of ALKS 2680 in Adults With Narcolepsy Type 1 (Brilliance NT1 - 304)

EUS Examination Using EndoSound Vision System vs. Standard Echoendoscope

Latino Teen Depression Treatment Study

Safety and Effectiveness of Mechanical Thrombectomy Using the Anaconda ANA Funnel Catheter

The Choice of Vasopressor to Prevent Postoperative Acute Kidney Injury After Major Non-Cardiac Surgery

Examining Mu Opioid Mechanisms of Ketamine's Rapid Effects in OCD (MKET2)

IGFBP-2 Vaccine to Prevent Ovarian Cancer Progression in Patients With Serologic Detection of Recurrence

Neuroimaging of Parkinson's

'Eat Well' Produce Prescription RCT

The Modulatory Effect of Female Sex Hormones on Spinal Neuroplasticity

A Mobile Patient Health Technology Intervention for Improving Lung Cancer Screening Rates in Eligible High Risk Patients

Thyroid Hormone for Treatment of Nonalcoholic Steatohepatitis in Veterans

Identifying Challenges to Healthy Aging in Persons With Human Immunodeficiency Virus (HIV) Age 50 and Older

PopSci CHW4CervixHealth

Patient Decision Aid in Supporting Decision-Making About When to Start or Stop New Drugs, Join Clinical Trials, or Continue Active Surveillance in Patients With Medullary Thyroid Cancer and Their Caregivers

Treatment and Secondary Prevention of Venous Thromboembolism (VTE) in Adult Participants With Solid and Hematologic Cancers

Type 1 Diabetes REst for Metabolic Health

Anastrazole, Fulvestrant & Abemaciclib for HR+HER2- Metastatic Breast Cancer